Compare ASUR & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | SIGA |
|---|---|---|
| Founded | 1985 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.4M | 223.8M |
| IPO Year | 1996 | 2016 |
| Metric | ASUR | SIGA |
|---|---|---|
| Price | $8.68 | $2.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | 96.7K | ★ 783.3K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $88,952,000.00 | N/A |
| Revenue This Year | $16.33 | N/A |
| Revenue Next Year | $9.20 | $224.81 |
| P/E Ratio | ★ N/A | $22.08 |
| Revenue Growth | ★ 63.39 | N/A |
| 52 Week Low | $6.80 | $2.83 |
| 52 Week High | $10.20 | $9.45 |
| Indicator | ASUR | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 28.92 |
| Support Level | $7.35 | N/A |
| Resistance Level | $8.81 | $4.84 |
| Average True Range (ATR) | 0.52 | 0.15 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 70.89 | 10.83 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its products majorly in the United States.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.